The global c-reactive protein testing market was valued at $2,765.07 million in 2020, and is estimated to reach $3,568.69 million by 2030, growing at a CAGR of 2.4% from 2021 to 2030. C-reactive protein (CRP) is a ring shaped pentameric protein present in the blood plasma whose levels rise in reaction to inflammation. It is produced by the liver and is a hepatic acute phase protein that rises in response to macrophages and T cells secreting interleukin. Inflammation is the body's way of protecting tissues after an injury or infection. It can also be caused by autoimmune disorders and various chronic diseases such as cardiovascular diseases, diabetes, and rheumatoid arthritis. CRP test measures the level of CRP in the blood caused in reaction to an inflammation.
CRP has anti-inflammatory as well as pro-inflammatory properties. It facilitates in recognition and removal of foreign pathogens and damaged cells. CRP levels of less than 0.3 mg/L are considered normal and are found in majority of healthy adults. Normal or minor elevation is defined as 0.3 to 1.0 mg/L and can be seen in obesity, pregnancy, depression, diabetes, common cold, sedentary lifestyle, and cigarette smoking. 1.0 to 10.0 mg/L is a moderate elevation caused primarily by systemic inflammation or other autoimmune diseases, malignancies, myocardial infarction, pancreatitis, and bronchitis. A level of more than 10.0 mg/L, indicating a significant elevation, is caused primarily by acute bacterial infections, viral infections, systemic vasculitis, and major trauma. A level of more than 50.0 mg/L indicates a severe elevation caused by acute bacterial infections.
Factors that drive growth of the market include increase in prevalence of inflammatory disorders and rise in cardiovascular diseases, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. For instance, according to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death worldwide, with an estimated 17.9 million people dying from CVDs in 2019, accounting for 32% of all global deaths. 85% of these deaths were caused by a heart attack or a stroke. In addition, according to the Center for Disease Control and Prevention, coronary heart disease is the most common type of heart disease, killing 360,900 people in 2019, and around 18.2 million adults aged 20 or older have CAD in the U.S. Thus, such significantly high rates of cardiac diseases boost the CRP testing market as CRP levels can indicate how vulnerable an individual is for developing cardiovascular problems. However, wide range of availability and advancement in other testing methods for cardiac diseases such as electrocardiogram (ECG) exercise stress test, echocardiogram (ultrasound), magnetic resonance imaging (MRI), coronary computed tomography angiogram (CCTA) and their rapid, accurate results is expected to restrain the market growth.
Other factors that propel the market growth include increase in unhealthy lifestyle among population; growth in chronic disorders, early diagnosis of medical conditions; and various initiatives taken by governments, non-profit organizations, and key players to increase the testing of CRP to detect various anomalies such as estimation of having a stroke or cardiac arrests in future, lupus, or other diseases by spreading awareness regarding the same.
Furthermore, technological advancements in diagnostics, adoption of point of care devices, collaborations, and product approvals further boost the market growth. For instance, in January 2022, LumiraDx announced that it received CE mark approval for its LumiraDx C-reactive protein test. It is a small and portable microfluidic immunoassay test used for quantitative determination of C-reactive protein, delivering results within four minutes. Thus, such approvals further boost availability and number of CRP testings and propels the market.
However, lack of public awareness and availability of alternative disease testing methods are expected to impede growth of the market. Furthermore, increase in applications for test, point of care testing, large target populations, higher global health care awareness, presence of a plethora of products in the pipeline, and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.
The global C-reactive protein testing market is segmented on the basis of assay type, application, and region. On the basis of assay type, the market is categorized into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assay, and others. By application, it is divided into diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
The major players profiled in the report are Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche AG, Horiba, Ltd., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Merck KGAA (Millipore Sigma), Randox Laboratories Limited, Thermo Fisher Scientific, Inc., and Zoetis Inc. (Abaxis Inc.).
CRP has anti-inflammatory as well as pro-inflammatory properties. It facilitates in recognition and removal of foreign pathogens and damaged cells. CRP levels of less than 0.3 mg/L are considered normal and are found in majority of healthy adults. Normal or minor elevation is defined as 0.3 to 1.0 mg/L and can be seen in obesity, pregnancy, depression, diabetes, common cold, sedentary lifestyle, and cigarette smoking. 1.0 to 10.0 mg/L is a moderate elevation caused primarily by systemic inflammation or other autoimmune diseases, malignancies, myocardial infarction, pancreatitis, and bronchitis. A level of more than 10.0 mg/L, indicating a significant elevation, is caused primarily by acute bacterial infections, viral infections, systemic vasculitis, and major trauma. A level of more than 50.0 mg/L indicates a severe elevation caused by acute bacterial infections.
Factors that drive growth of the market include increase in prevalence of inflammatory disorders and rise in cardiovascular diseases, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. For instance, according to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death worldwide, with an estimated 17.9 million people dying from CVDs in 2019, accounting for 32% of all global deaths. 85% of these deaths were caused by a heart attack or a stroke. In addition, according to the Center for Disease Control and Prevention, coronary heart disease is the most common type of heart disease, killing 360,900 people in 2019, and around 18.2 million adults aged 20 or older have CAD in the U.S. Thus, such significantly high rates of cardiac diseases boost the CRP testing market as CRP levels can indicate how vulnerable an individual is for developing cardiovascular problems. However, wide range of availability and advancement in other testing methods for cardiac diseases such as electrocardiogram (ECG) exercise stress test, echocardiogram (ultrasound), magnetic resonance imaging (MRI), coronary computed tomography angiogram (CCTA) and their rapid, accurate results is expected to restrain the market growth.
Other factors that propel the market growth include increase in unhealthy lifestyle among population; growth in chronic disorders, early diagnosis of medical conditions; and various initiatives taken by governments, non-profit organizations, and key players to increase the testing of CRP to detect various anomalies such as estimation of having a stroke or cardiac arrests in future, lupus, or other diseases by spreading awareness regarding the same.
Furthermore, technological advancements in diagnostics, adoption of point of care devices, collaborations, and product approvals further boost the market growth. For instance, in January 2022, LumiraDx announced that it received CE mark approval for its LumiraDx C-reactive protein test. It is a small and portable microfluidic immunoassay test used for quantitative determination of C-reactive protein, delivering results within four minutes. Thus, such approvals further boost availability and number of CRP testings and propels the market.
However, lack of public awareness and availability of alternative disease testing methods are expected to impede growth of the market. Furthermore, increase in applications for test, point of care testing, large target populations, higher global health care awareness, presence of a plethora of products in the pipeline, and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.
The global C-reactive protein testing market is segmented on the basis of assay type, application, and region. On the basis of assay type, the market is categorized into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assay, and others. By application, it is divided into diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
The major players profiled in the report are Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche AG, Horiba, Ltd., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Merck KGAA (Millipore Sigma), Randox Laboratories Limited, Thermo Fisher Scientific, Inc., and Zoetis Inc. (Abaxis Inc.).
KEY BENEFITS FOR STAKEHOLDERS
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global benign prostatic hyperplasia therapeutics market to identify the prevailing opportunities
- This study presents the competitive landscape of the global market to predict the competitive environment across geographies
- Comprehensive analysis of factors that drive and restrict the market growth is provided
- Region & country-wise analysis is provided to understand the market trends and dynamics
KEY MARKET SEGMENTS
By Assay Type
- Enzyme-linked immunosorbent assay (ELISA)
- Chemiluminescence immunoassay (CLIA)
- Immunoturbidimetric assays
- Others
By Application
- Diabetes
- Rheumatoid Arthritis
- Cardiovascular Disease
- Inflammatory Bowel Disease
- Others
By Region
- North America
- US
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
KEY MARKET PLAYERS
- Abbott Laboratories
- Danaher Corporation (Beckman Coulter Inc)
- F Hoffmann-La Roche AG
- Horiba, Ltd
- Quest Diagnostics Incorporated
- Merck KGAA (Millipore Sigma)
- Randox Laboratories Limited
- Laboratory Corporation of America Holdings
- Thermo Fisher Scientific, Inc
- Zoetis Inc (Abaxis Inc)
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Landscape
Chapter 4: C-Reactive Protein Testing Market, by Assay Type
Chapter 5: C-Reactive Protein Testing Market, by Application
Chapter 6: C-Reactive Protein Testing Market, by Region
Chapter 7: Company Profiles
List of Tables
List of Figures
Executive Summary
According to a new report titled, C-Reactive Protein Testing Market by, Assay Type, Application and Region: Global Opportunity Analysis and Industry Forecast, 2021–2030, the global C-reactive protein testing market size was valued at $2,765.07 million in 2020, and is projected to reach $3,568.69 million by 2030, registering a CAGR of 2.4% from 2021 to 2030.C-reactive protein (CRP), an acute phase protein is primarily induced during acute phase of an inflammatory/infectious process by the action of Interleukin IL-6 on the gene responsible for CRP transcription. C-reactive protein test is used to determine concentration of CRP in blood plasma. CRP is an acute inflammatory protein that can multiply up to 1,000-fold in areas of infection or inflammation. The test is used to determine the infection and other medical conditions. The test does not specify direct cause of inflammation, but indicates the level of inflammation caused by other factors. It is a reliable early indicator of inflammation or injury.
Growth of the C-reactive protein testing market is majorly driven, owing to rise in prevalence of chronic diseases such as diabetes, rheumatoid arthritis, endometriosis, cardiovascular disease, inflammatory bowel disease, and other diseases. Increase in unhealthy lifestyle, poor eating habits, rise in stress, and adoption of sedentary lifestyle has led to increase in number of chronic diseases globally.
For instance, according to the Centers for Disease Control and Prevention in 2021, one in every four adults in the U.S., which is 23.7% or approximately 58.5 million people, have arthritis. Arthritis is more common in women (23.5%) than in men (18.1%) and more common in adults with fair/poor health (40.5%) than in those with excellent/very good health (15.4%). Furthermore, prevalence of arthritis rises with age. In the coming decades, the prevalence of doctor-diagnosed arthritis is expected to rise significantly. By 2040, an estimated 78.4 million adults aged 18 and older, which is 25.9% of the projected total adult population will have doctor-diagnosed arthritis, up from 58.5 million adults from 2013 to 2015. Thus, rise of such cases is expected to significantly increase the number of CRP testing and further drive the c-reactive protein testing market growth during the forecast period.
In addition, technological advancements for CRP testing, development, and launch of various products further drive the market growth. For instance, in September 2021, HORIBA UK Limited launched its new generation Microsemi CRP point-of-care hematology analyzer. It is nearly 25% more compact and includes improved software with network connectivity, resulting in improved usability and increased memory capacity. A new parameter, granulocytes-to-lymphocytes ratio (GLR), has been added to its suite of 20 parameters to support COVID-19 patient assessment. All of this contributes toward increased functionality of new Microsemi CRPs and diagnostic efficiency in determining whether an infection or inflammation is viral or bacterial and determining the appropriate antibiotic therapy at the point-of-care. Its delivers results in just four minutes, combined with comprehensive data management and enables clinicians to initiate more rapid treatment decisions. Thus, launch of such products further propel growth of the C-reactive protein testing market.
However, lack of public awareness is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and government initiatives for health awareness is expected to provide many opportunities during the forecast period.
By assay type, the c-reactive protein testing market is segmented into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assay, and others. The immunoturbidimetric assay segment generated maximum revenue in 2020, accounting $1276.57 million. The chemiluminescence immunoassay (CLIA) segment is expected to witness highest CAGR of 3.60% during the forecast period.
Depending on application, the c-reactive protein testing market is divided into diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, and others. The cardiovascular disease segment dominated the market in 2020, with $1,793.88 million and is expected to witness CAGR of 2.10% during the forecast period.
North America accounted for a majority of the global c-reactive protein testing market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of inflammatory diseases, increase in unhealthy lifestyle, development of new solutions for detection, presence of key players, and rise in healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in chronic diseases, rise in R&D activities, and increase in investments in the healthcare sector in the region
Key Findings Of The Study
- By assay type, immunoturbidimetric assay was the highest contributor to the c-reactive protein testing market in 2020
- By application, cardiovascular disease segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period
- By region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
Companies Mentioned
- Abbott Laboratories
- Danaher Corporation (Beckman Coulter Inc.)
- F. Hoffmann-La Roche AG
- Horiba, Ltd.
- Quest Diagnostics Incorporated
- Merck KGAA (Millipore Sigma)
- Randox Laboratories Limited
- Laboratory Corporation of America Holdings
- Thermo Fisher Scientific, Inc.
- Zoetis Inc. (Abaxis Inc.).
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 229 |
| Published | February 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 2765.07 million |
| Forecasted Market Value ( USD | $ 3568.69 million |
| Compound Annual Growth Rate | 2.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
